Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07258836 | A Study of [18F]LY4214835 in Healthy Volunteers and Participants With Cancer | PHASE1 | RECRUITING | 41 | — | — | Dec 22, 2025 | Jan 1, 2027 | Apr 17, 2026 | 6 | United States |
Evaluation of AEs regardless of causality, will be reported in the Reported AEs module
Determination of the radiation dosimetry absorbed dose in body organs and whole-body effective dose
| Arm | Type | Description |
|---|---|---|
| LY4214835 (Cohorts 1 and 2) | EXPERIMENTAL | LY4214835 administered intravenously (IV) |
| Name | Type | Description |
|---|---|---|
| LY4214835 | DRUG | Administered IV |
Inclusion Criteria: * Cohort 1 * Have a radiologically, cytologically, or histologically confirmed diagnosis of cancer * Are treatment-naïve to a systemic cancer therapy, OR have a documented disease progression on standard-of-care treatment (for example, failure of chemotherapy, targeted ther...